Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not hyperglycemia

Research output: Contribution to journalJournal articlepeer-review

Standard

Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not hyperglycemia. / Stinson, Sara E; Jonsson, Anna E.; Alzola, Ierai Fernández de Retana; Lund, Morten A V; Frithioff-Bøjsøe, Christine; Holm, Louise Aas; Fonvig, Cilius E.; Pedersen, Oluf; Ängquist, Lars; Sørensen, Thorkild I A; Holst, Jens J; Christiansen, Michael; Holm, Jens-Christian; Hartmann, Bolette; Hansen, Torben.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 107, No. 6, 2022, p. 1569–1576.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Stinson, SE, Jonsson, AE, Alzola, IFDR, Lund, MAV, Frithioff-Bøjsøe, C, Holm, LA, Fonvig, CE, Pedersen, O, Ängquist, L, Sørensen, TIA, Holst, JJ, Christiansen, M, Holm, J-C, Hartmann, B & Hansen, T 2022, 'Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not hyperglycemia', Journal of Clinical Endocrinology and Metabolism, vol. 107, no. 6, pp. 1569–1576. https://doi.org/10.1210/clinem/dgac108

APA

Stinson, S. E., Jonsson, A. E., Alzola, I. F. D. R., Lund, M. A. V., Frithioff-Bøjsøe, C., Holm, L. A., Fonvig, C. E., Pedersen, O., Ängquist, L., Sørensen, T. I. A., Holst, J. J., Christiansen, M., Holm, J-C., Hartmann, B., & Hansen, T. (2022). Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not hyperglycemia. Journal of Clinical Endocrinology and Metabolism, 107(6), 1569–1576. https://doi.org/10.1210/clinem/dgac108

Vancouver

Stinson SE, Jonsson AE, Alzola IFDR, Lund MAV, Frithioff-Bøjsøe C, Holm LA et al. Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not hyperglycemia. Journal of Clinical Endocrinology and Metabolism. 2022;107(6):1569–1576. https://doi.org/10.1210/clinem/dgac108

Author

Stinson, Sara E ; Jonsson, Anna E. ; Alzola, Ierai Fernández de Retana ; Lund, Morten A V ; Frithioff-Bøjsøe, Christine ; Holm, Louise Aas ; Fonvig, Cilius E. ; Pedersen, Oluf ; Ängquist, Lars ; Sørensen, Thorkild I A ; Holst, Jens J ; Christiansen, Michael ; Holm, Jens-Christian ; Hartmann, Bolette ; Hansen, Torben. / Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not hyperglycemia. In: Journal of Clinical Endocrinology and Metabolism. 2022 ; Vol. 107, No. 6. pp. 1569–1576.

Bibtex

@article{bb76412551be41739a31aa6b81c6fc65,
title = "Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not hyperglycemia",
abstract = "CONTEXT: In adults, hyperglucagonemia is associated with type 2 diabetes, impaired glucose tolerance, and obesity. The role of glucagon in pediatric overweight/obesity remains unclear.OBJECTIVE: We examined whether fasting concentrations of glucagon are elevated in youth with overweight/obesity and whether this associates with cardiometabolic risk profiles.METHODS: Analyses were based on the cross-sectional HOLBAEK Study, including 6-19-year-old children and adolescents with overweight/obesity from an obesity clinic group (n = 2154) and a population-based group with normal weight (n = 1858). Fasting concentrations of plasma glucagon and cardiometabolic risk outcomes were assessed, multiple linear and logistic regressions models were performed.RESULTS: The obesity clinic group had higher glucagon concentrations than the population-based group (P < 0.001). Glucagon positively associated with BMI standard deviation score (SDS), waist, body fat %, liver fat %, alanine transaminase (ALT), high-sensitivity C-reactive protein, homeostasis model assessment of insulin resistance, insulin, C-peptide, LDL-C, triglycerides, SDS of diastolic and systolic blood pressure, and was inversely associated with fasting glucose. The inverse relationship between glucagon and glucose was attenuated in individuals with high BMI SDS and high fasting insulin. Glucagon was associated with a higher prevalence of insulin resistance, increased ALT, dyslipidemia, and hypertension, but not with hyperglycemia. Glucagon was positively associated with fasting total glucagon-like peptide-1.CONCLUSIONS: Compared to normal weight peers, children and adolescents with overweight/obesity had elevated concentrations of fasting glucagon, which corresponded to worsened cardiometabolic risk outcomes, except for hyperglycemia. This suggests hyperglucagonemia in youth may precede impairments in glucose regulation.",
author = "Stinson, {Sara E} and Jonsson, {Anna E.} and Alzola, {Ierai Fern{\'a}ndez de Retana} and Lund, {Morten A V} and Christine Frithioff-B{\o}js{\o}e and Holm, {Louise Aas} and Fonvig, {Cilius E.} and Oluf Pedersen and Lars {\"A}ngquist and S{\o}rensen, {Thorkild I A} and Holst, {Jens J} and Michael Christiansen and Jens-Christian Holm and Bolette Hartmann and Torben Hansen",
note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.",
year = "2022",
doi = "10.1210/clinem/dgac108",
language = "English",
volume = "107",
pages = "1569–1576",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "6",

}

RIS

TY - JOUR

T1 - Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not hyperglycemia

AU - Stinson, Sara E

AU - Jonsson, Anna E.

AU - Alzola, Ierai Fernández de Retana

AU - Lund, Morten A V

AU - Frithioff-Bøjsøe, Christine

AU - Holm, Louise Aas

AU - Fonvig, Cilius E.

AU - Pedersen, Oluf

AU - Ängquist, Lars

AU - Sørensen, Thorkild I A

AU - Holst, Jens J

AU - Christiansen, Michael

AU - Holm, Jens-Christian

AU - Hartmann, Bolette

AU - Hansen, Torben

N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.

PY - 2022

Y1 - 2022

N2 - CONTEXT: In adults, hyperglucagonemia is associated with type 2 diabetes, impaired glucose tolerance, and obesity. The role of glucagon in pediatric overweight/obesity remains unclear.OBJECTIVE: We examined whether fasting concentrations of glucagon are elevated in youth with overweight/obesity and whether this associates with cardiometabolic risk profiles.METHODS: Analyses were based on the cross-sectional HOLBAEK Study, including 6-19-year-old children and adolescents with overweight/obesity from an obesity clinic group (n = 2154) and a population-based group with normal weight (n = 1858). Fasting concentrations of plasma glucagon and cardiometabolic risk outcomes were assessed, multiple linear and logistic regressions models were performed.RESULTS: The obesity clinic group had higher glucagon concentrations than the population-based group (P < 0.001). Glucagon positively associated with BMI standard deviation score (SDS), waist, body fat %, liver fat %, alanine transaminase (ALT), high-sensitivity C-reactive protein, homeostasis model assessment of insulin resistance, insulin, C-peptide, LDL-C, triglycerides, SDS of diastolic and systolic blood pressure, and was inversely associated with fasting glucose. The inverse relationship between glucagon and glucose was attenuated in individuals with high BMI SDS and high fasting insulin. Glucagon was associated with a higher prevalence of insulin resistance, increased ALT, dyslipidemia, and hypertension, but not with hyperglycemia. Glucagon was positively associated with fasting total glucagon-like peptide-1.CONCLUSIONS: Compared to normal weight peers, children and adolescents with overweight/obesity had elevated concentrations of fasting glucagon, which corresponded to worsened cardiometabolic risk outcomes, except for hyperglycemia. This suggests hyperglucagonemia in youth may precede impairments in glucose regulation.

AB - CONTEXT: In adults, hyperglucagonemia is associated with type 2 diabetes, impaired glucose tolerance, and obesity. The role of glucagon in pediatric overweight/obesity remains unclear.OBJECTIVE: We examined whether fasting concentrations of glucagon are elevated in youth with overweight/obesity and whether this associates with cardiometabolic risk profiles.METHODS: Analyses were based on the cross-sectional HOLBAEK Study, including 6-19-year-old children and adolescents with overweight/obesity from an obesity clinic group (n = 2154) and a population-based group with normal weight (n = 1858). Fasting concentrations of plasma glucagon and cardiometabolic risk outcomes were assessed, multiple linear and logistic regressions models were performed.RESULTS: The obesity clinic group had higher glucagon concentrations than the population-based group (P < 0.001). Glucagon positively associated with BMI standard deviation score (SDS), waist, body fat %, liver fat %, alanine transaminase (ALT), high-sensitivity C-reactive protein, homeostasis model assessment of insulin resistance, insulin, C-peptide, LDL-C, triglycerides, SDS of diastolic and systolic blood pressure, and was inversely associated with fasting glucose. The inverse relationship between glucagon and glucose was attenuated in individuals with high BMI SDS and high fasting insulin. Glucagon was associated with a higher prevalence of insulin resistance, increased ALT, dyslipidemia, and hypertension, but not with hyperglycemia. Glucagon was positively associated with fasting total glucagon-like peptide-1.CONCLUSIONS: Compared to normal weight peers, children and adolescents with overweight/obesity had elevated concentrations of fasting glucagon, which corresponded to worsened cardiometabolic risk outcomes, except for hyperglycemia. This suggests hyperglucagonemia in youth may precede impairments in glucose regulation.

U2 - 10.1210/clinem/dgac108

DO - 10.1210/clinem/dgac108

M3 - Journal article

C2 - 35213713

VL - 107

SP - 1569

EP - 1576

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -

ID: 300012430